Evergreening: How Pharmaceutical Brands Delay Generic Drugs to Protect Profits

When a life-saving drug loses its patent, prices should drop - often by 80% or more. But in many cases, they don’t. That’s not because no one can make the generic version. It’s because the brand company has spent years quietly building a wall of patents around the same old drug, stretching its monopoly far beyond what Congress intended. This isn’t innovation. It’s evergreening.

What Evergreening Really Means

Evergreening isn’t a dirty secret. It’s a documented, widespread practice. When a drug’s original 20-year patent is about to expire, pharmaceutical companies file new patents on tiny changes - a slightly different pill coating, a new dosage timing, or a combination with another common ingredient. These aren’t breakthroughs. They’re tweaks. But under U.S. patent law, even minor modifications can earn a new 20-year monopoly.

Take AstraZeneca’s Prilosec, a blockbuster drug for acid reflux. When its patent neared expiration, the company rolled out Nexium - a chemically similar version with a single atom changed. Nexium wasn’t more effective. It wasn’t safer. But it came with a new patent. Patients paid $300 a month for Nexium, while the generic Prilosec cost $10. That’s not a better drug. That’s a price lock.

Harvard researchers found that 78% of new patents filed for prescription drugs between 2005 and 2015 were for drugs already on the market. Not new treatments. Same drugs, new paperwork.

How It Works: The Patent Playbook

Companies don’t just file one new patent. They file dozens. The goal? A patent thicket - a tangled web of overlapping protections that makes it too expensive and risky for generic makers to challenge them all.

AbbVie’s Humira, a drug for rheumatoid arthritis and Crohn’s disease, is the most extreme example. The company filed 247 patents on this one drug. Over 100 were granted. That’s not innovation. That’s legal obstruction. Humira became the best-selling drug in history - earning $40 million a day - not because it was revolutionary, but because generics couldn’t break through.

Here’s how the playbook usually unfolds:

• New formulation: Change the pill’s release time - say, from immediate to extended-release. Patent it.
• New delivery method: Switch from a pill to an injectable pen. Patent it.
• New combination: Bundle the drug with another common medication. Patent the combo.
• Pediatric extension: Run a small study in kids. Get six extra months.
• Orphan drug status: Repurpose the drug for a rare condition. Get seven years of exclusivity.
• Authorized generics: Let your own subsidiary make the generic - but sell it at full price under a different name.

These aren’t loopholes. They’re features of the system. The 1984 Hatch-Waxman Act was meant to balance innovation with access. But companies learned how to game it.

Why It Matters: Real People Pay the Price

Every time a brand delays a generic, real people go without treatment. A diabetic in rural Ohio can’t afford the $900 monthly cost of a branded insulin when the generic version costs $35. A veteran with psoriasis skips doses because the $12,000-a-year biologic isn’t covered. These aren’t edge cases. They’re routine.

Generic drugs enter the market at 80-85% lower prices. That’s not speculation. It’s data. When Humira finally lost patent protection in 2023, its price dropped nearly 70% in just six months. That’s what competition does. But for over 15 years, patients paid the cost of AbbVie’s patent thicket.

And it’s not just about money. When generics are blocked, patients are forced to use more expensive alternatives - often with worse side effects or less proven results. That’s not healthcare. That’s profit-driven rationing.

Who Benefits? Who Loses?

Let’s be clear: the winners are shareholders and CEOs. The losers are patients, insurers, and public health systems.

Pharmaceutical companies argue they need long exclusivity to fund research. But here’s the math:

• Developing a brand-new drug costs about $2.6 billion and takes 10-15 years.
• Evergreening a drug costs less than $50 million and takes 1-3 years.

That’s not innovation. That’s arbitrage. Companies are investing in lawyers, not labs. They’re not discovering new molecules - they’re tweaking old ones and calling them inventions.

The U.S. government spends over $1 trillion a year on healthcare. Drug prices account for nearly 20% of that. Evergreening is one of the biggest drivers of that cost. And it’s not just America. The World Health Organization called it a barrier to medicine access in low-income countries - where people pay 10 times more for the same drug because generics can’t enter.

Is There Any Pushback?

Yes - but it’s slow.

In 2022, the U.S. Federal Trade Commission sued AbbVie over Humira’s patent strategy, calling it an “anticompetitive scheme.” The case is still ongoing. The Inflation Reduction Act of 2022 gave Medicare the power to negotiate prices for 10 high-cost drugs - a direct blow to evergreening’s profitability. The European Medicines Agency now requires proof of “significant clinical benefit” before granting extra exclusivity.

But companies adapt. They’re moving into biologics - complex drugs made from living cells. These are harder to copy. They’re patenting genetic tests that predict who responds to a drug - effectively locking out generics by making them “untested.” They’re even using nanotechnology to create “next-gen” versions that look different but work the same.

It’s a game of whack-a-mole. Every time regulators close one loophole, companies drill another.

What’s Next?

Patients won’t win until the system changes. Here’s what needs to happen:

• Stricter patent standards: The U.S. Patent Office must stop granting patents on trivial changes. If a tweak doesn’t improve safety or effectiveness, it shouldn’t get a new monopoly.
• Limit patent stacking: No drug should get more than one extension. Period.
• Transparency: All patent filings tied to a single drug should be publicly listed and reviewed together - not buried in dozens of separate applications.
• Global pressure: Countries must stop accepting U.S.-style patent extensions. The WHO is right: access to medicine is a human right, not a corporate asset.

Some companies are starting to shift. A few are investing in true innovation. But most still rely on evergreening. It’s too easy. Too profitable. Too broken.

The system was built to reward innovation. Now it rewards legal cleverness. And while lawyers and CEOs celebrate, patients wait - and pay.